MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaci.2019.01.051

Медицинская библиотека · The Journal of allergy and clinical immunology · 2019

Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies.

Milito Cinzia, Pulvirenti Federica, Cinetto Francesco, Lougaris Vassilios, Soresina Annarosa, Pecoraro Antonio, Vultaggio Alessandra, Carrabba Maria, Lassandro Giuseppe, Plebani Alessandro, Spadaro Giuseppe, Matucci Andrea, Fabio Giovanna, Dellepiane Rosa Maria, Martire Baldassarre, Agostini Carlo, Abeni Damiano, Tabolli Stefano, Quinti Isabella

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Lacking protective antibodies, patients with primary antibody deficiencies (PADs) experience frequent respiratory tract infections, leading to chronic pulmonary damage. Macrolide prophylaxis has proved effective in patients with chronic respiratory diseases.

OBJECTIVE

We aimed to test the efficacy and safety of orally administered low-dose azithromycin prophylaxis in patients with PADs.

METHODS

We designed a 3-year, double-blind, placebo-controlled, randomized clinical trial to test whether oral azithromycin (250 mg administered once daily 3 times a week for 2 years) would reduce respiratory exacerbations in patients with PADs and chronic infection-related pulmonary diseases. The primary end point was the number of annual respiratory exacerbations. Secondary end points included time to first exacerbation, additional antibiotic courses, number of hospitalizations, and safety.

RESULTS

Eighty-nine patients received azithromycin (n = 44) or placebo (n = 45). The number of exacerbations was 3.6 (95% CI, 2.5-4.7) per patient-year in the azithromycin arm and 5.2 (95% CI, 4.1-6.4) per patient-year in the placebo arm (P = .02). In the azithromycin group the hazard risk for having an acute exacerbation was 0.5 (95% CI, 0.3-0.9; P = .03), and the hazard risk for hospitalization was 0.5 (95% CI, 0.2-1.1; P = .04). The rate of additional antibiotic treatment per patient-year was 2.3 (95% CI, 2.1-3.4) in the intervention group and 3.6 (95% CI, 2.9-4.3) in the placebo group (P = .004). Haemophilus influenzae and Streptococcus pneumoniae were the prevalent isolates, and they were not susceptible to macrolides in 25% of patients of both arms. Azithromycin's safety profile was comparable with that of placebo.

CONCLUSION

The study reached the main outcome centered on the reduction of exacerbation episodes per patient-year, with a consequent reduction in additional courses of antibiotics and risk of hospitalization.

Для цитирования: Milito Cinzia, Pulvirenti Federica, Cinetto Francesco, Lougaris Vassilios, Soresina Annarosa, Pecoraro Antonio, Vultaggio Alessandra, Carrabba Maria, Lassandro Giuseppe, Plebani Alessandro, Spadaro Giuseppe, Matucci Andrea, Fabio Giovanna, Dellepiane Rosa Maria, Martire Baldassarre, Agostini Carlo, Abeni Damiano, Tabolli Stefano, Quinti Isabella. Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies.. The Journal of allergy and clinical immunology. 2019. DOI: 10.1016/j.jaci.2019.01.051.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.